---
id: doc-robbins-treatment-plan-1976-10-15
guid: n/a
type: personal
subtype: medical-record
title: Chemotherapy Treatment Plan for Carl Robbins III
author: Dr. Sarah Williams
recipient: Donna Robbins
organization: Massachusetts General Hospital
date: 1976-10-15
timestamp: 1976-10-15_14:00
period: period-4
related_legal_elements: Conscious Pain and Suffering, Damages
---

# MASSACHUSETTS GENERAL HOSPITAL
## Department of Pediatric Oncology
### 55 Fruit Street, Boston, Massachusetts 02114

---

**PATIENT:** Carl Robbins III  
**MEDICAL RECORD NUMBER:** 7610-4829  
**DATE OF BIRTH:** March 12, 1968  
**AGE:** 8 years, 7 months  
**PARENT/GUARDIAN:** Donna Robbins  
**ADDRESS:** 42 Pine Street, Woburn, Massachusetts 01801  
**DATE:** October 15, 1976  
**TIME:** 2:00 PM  
**ATTENDING PHYSICIAN:** Dr. Sarah Williams, MD  

---

## DIAGNOSIS

Primary Diagnosis: Acute Lymphocytic Leukemia (ALL), diagnosed September 3, 1976

Secondary Diagnoses:
- Anemia secondary to chemotherapy
- Neutropenia
- Thrombocytopenia

## TREATMENT HISTORY

Carl was admitted to Massachusetts General Hospital on September 1, 1976, presenting with a two-week history of fatigue, pallor, and recurrent fevers. Laboratory studies revealed a white blood cell count of 47,000 with 85% lymphoblasts. Bone marrow biopsy confirmed the diagnosis of acute lymphocytic leukemia on September 3, 1976.

Initial treatment commenced immediately with the standard ALL protocol consisting of vincristine, prednisone, and L-asparaginase for induction therapy. Carl achieved morphologic remission after four weeks of treatment, with bone marrow biopsy on October 1, 1976, showing less than 5% lymphoblasts.

## CURRENT TREATMENT PLAN

**Phase:** Consolidation Therapy (commenced October 8, 1976)

**Chemotherapy Regimen:**
- Methotrexate 20 mg/m² intrathecally every 2 weeks
- Mercaptopurine 75 mg/m² orally daily
- Vincristine 1.5 mg/m² intravenously weekly for 4 weeks
- Prednisone 40 mg/m² orally daily for 28 days, then taper

**Monitoring Requirements:**
- Complete blood count with differential twice weekly
- Liver function tests weekly
- Renal function assessment weekly
- Neurological examination prior to each intrathecal injection

**Supportive Care:**
- Allopurinol 300 mg orally daily for tumor lysis prevention
- Trimethoprim-sulfamethoxazole prophylaxis against Pneumocystis carinii
- Nutritional counseling and supplementation as needed
- Psychological support services for patient and family

## CLINICAL OBSERVATIONS

Carl has tolerated the initial induction therapy reasonably well, though he has experienced significant side effects consistent with his treatment regimen. During hospitalization, he developed mucositis requiring morphine for pain control and necessitating temporary cessation of oral intake. His white blood cell count nadired at 800 on September 28, requiring isolation precautions and prophylactic antibiotics.

The patient has lost approximately 12 pounds since diagnosis, representing a 15% decrease from his baseline weight of 78 pounds. His energy levels remain significantly diminished, and he experiences daily nausea requiring antiemetic medication. Hair loss began during the second week of treatment and is now complete.

Mrs. Robbins reports that Carl experiences significant anxiety regarding medical procedures, particularly venipunctures and bone marrow aspirations. He has required sedation for recent procedures due to his distress. Sleep disturbances are common, with frequent nightmares and difficulty falling asleep.

## PROGNOSIS AND TREATMENT GOALS

The overall prognosis for pediatric ALL has improved significantly in recent years, with current protocols achieving remission rates of approximately 90% and long-term survival rates approaching 50-60%. Carl's initial response to induction therapy is encouraging, and his age and presenting white blood cell count place him in a favorable risk category.

The immediate treatment goals include:
1. Maintenance of remission through consolidation therapy
2. Prevention of central nervous system involvement
3. Management of treatment-related toxicities
4. Preservation of quality of life during treatment
5. Preparation for maintenance therapy phase

## FAMILY CONFERENCE DISCUSSION

I met with Mrs. Robbins today to discuss Carl's treatment plan and prognosis. She expressed significant concerns about the intensity of the treatment regimen and its impact on Carl's daily functioning. We discussed the necessity of aggressive treatment to achieve cure, while acknowledging the substantial physical and emotional toll on both Carl and the family.

Mrs. Robbins reported financial strain related to medical expenses and her inability to maintain full-time employment while caring for Carl. Social services consultation has been arranged to explore available assistance programs.

The family has questions about environmental factors that might have contributed to Carl's illness, noting that several children in their East Woburn neighborhood have been diagnosed with leukemia in recent years. I have referred them to the Massachusetts Department of Public Health for information about ongoing investigations into potential environmental health concerns in their area.

## PAIN AND SYMPTOM MANAGEMENT

Carl experiences multiple sources of discomfort related to both his disease and treatment:

**Procedure-Related Pain:**
- Bone marrow aspirations cause severe pain despite local anesthesia
- Lumbar punctures for intrathecal chemotherapy result in headaches lasting 24-48 hours
- Venipunctures are increasingly difficult due to poor venous access

**Treatment-Related Symptoms:**
- Severe nausea and vomiting requiring multiple antiemetic agents
- Oral mucositis causing difficulty eating and swallowing
- Peripheral neuropathy from vincristine causing numbness and tingling
- Fatigue and weakness limiting normal childhood activities

**Psychological Distress:**
- Anxiety regarding medical procedures and hospital visits
- Depression related to isolation from peers and normal activities
- Fear and confusion about his illness and treatment

Pain management strategies include:
- Morphine sulfate 0.1 mg/kg every 4 hours as needed for severe pain
- Compazine 0.15 mg/kg every 6 hours for nausea control
- Benadryl 1 mg/kg for anxiety before procedures
- Child life specialist involvement for coping strategies

## FOLLOW-UP CARE PLAN

**Immediate (Next 4 weeks):**
- Weekly clinic visits for chemotherapy administration
- Bi-weekly laboratory monitoring
- Assessment of treatment response and toxicities

**Intermediate (Months 2-6):**
- Transition to maintenance therapy if remission continues
- Bone marrow evaluation at 3-month intervals
- Growth and development monitoring

**Long-term:**
- Continued maintenance therapy for 2-3 years total
- Regular surveillance for late effects of treatment
- Educational and developmental support services

## MEDICAL NECESSITY STATEMENT

The prescribed chemotherapy regimen represents the current standard of care for pediatric acute lymphocytic leukemia and is medically necessary for Carl's survival. Any deviation from this protocol could result in disease relapse and potential death. The intensive nature of treatment, while causing significant side effects and suffering, offers the best opportunity for cure.

The financial burden on the family is substantial, with estimated treatment costs exceeding $25,000 for the first year alone. This figure does not include indirect costs such as lost wages, transportation, and supportive care needs.

## PHYSICIAN CERTIFICATION

I certify that the above treatment plan is medically necessary and appropriate for Carl Robbins III's condition. The prescribed medications and procedures are essential components of his cancer treatment and are being administered according to established pediatric oncology protocols.

The pain and suffering experienced by this child as a result of both his disease and its treatment are significant and ongoing. These effects impact not only Carl but extend to his entire family, who must witness his daily struggle with this devastating illness.

---

**Dr. Sarah Williams, MD**  
Chief, Pediatric Oncology  
Massachusetts General Hospital  
License #: MD-7429-1969  

**Date:** October 15, 1976  
**Time:** 2:00 PM

---

*This document contains confidential medical information protected by physician-patient privilege. Distribution is restricted to authorized medical personnel and the patient's legal representatives.*